|
Dear Reader :
As the year winds to a close Pharma Intelligence and the IPA wishes all members a joyous Christmas and plenty of holiday cheer!
This edition of the newsletter, developed in alliance with the IPA, brings you a riveting profile of Novo Nordisk’s third CEO, Mads Øvlisen, his life journey and how he helped shape the diabetes powerhouse. Øvlisen has some powerful and wise words for industry.
We also spotlight how RNA technologies have been a big driver of venture capital investment and there’s an interesting piece on why China’s immuno-oncology market still has room to mature.
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
|
